Mayne Pharma Group Stock Probability of Future Pink Sheet Price Finishing Under 0.03
| MAYNF Stock | USD 3.10 0.10 3.33% |
Mayne |
Mayne Pharma Target Price Odds to finish below 0.03
The tendency of Mayne Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 0.03 or more in 90 days |
| 3.10 | 90 days | 0.03 | near 1 |
Based on a normal probability distribution, the odds of Mayne Pharma to drop to $ 0.03 or more in 90 days from now is near 1 (This Mayne Pharma Group probability density function shows the probability of Mayne Pink Sheet to fall within a particular range of prices over 90 days) . Probability of Mayne Pharma Group price to stay between $ 0.03 and its current price of $3.1 at the end of the 90-day period is about 73.63 .
Assuming the 90 days horizon the pink sheet has the beta coefficient of 1.01 . This indicates Mayne Pharma Group market returns are reactive to returns on the market. As the market goes up or down, Mayne Pharma is expected to follow. Additionally Mayne Pharma Group has an alpha of 0.1408, implying that it can generate a 0.14 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Mayne Pharma Price Density |
| Price |
Predictive Modules for Mayne Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Mayne Pharma Group. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Mayne Pharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Mayne Pharma is not an exception. The market had few large corrections towards the Mayne Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Mayne Pharma Group, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Mayne Pharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.14 | |
β | Beta against Dow Jones | 1.01 | |
σ | Overall volatility | 0.30 | |
Ir | Information ratio | 0.03 |
Mayne Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Mayne Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Mayne Pharma Group can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Mayne Pharma Group had very high historical volatility over the last 90 days | |
| Mayne Pharma Group has high likelihood to experience some financial distress in the next 2 years | |
| Mayne Pharma Group has accumulated 413.67 M in total debt with debt to equity ratio (D/E) of 0.74, which is about average as compared to similar companies. Mayne Pharma Group has a current ratio of 0.82, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Mayne Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Mayne Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mayne Pharma Group sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mayne to invest in growth at high rates of return. When we think about Mayne Pharma's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 423.92 M. Net Loss for the year was (263.34 M) with profit before overhead, payroll, taxes, and interest of 171.03 M. | |
| Mayne Pharma Group has accumulated about 98.01 M in cash with (7.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06. | |
| Roughly 23.0% of Mayne Pharma outstanding shares are owned by corporate insiders |
Mayne Pharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Mayne Pink Sheet often depends not only on the future outlook of the current and potential Mayne Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Mayne Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.8 B |
Mayne Pharma Technical Analysis
Mayne Pharma's future price can be derived by breaking down and analyzing its technical indicators over time. Mayne Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Mayne Pharma Group. In general, you should focus on analyzing Mayne Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Mayne Pharma Predictive Forecast Models
Mayne Pharma's time-series forecasting models is one of many Mayne Pharma's pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Mayne Pharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Mayne Pharma Group
Checking the ongoing alerts about Mayne Pharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Mayne Pharma Group help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Mayne Pharma Group had very high historical volatility over the last 90 days | |
| Mayne Pharma Group has high likelihood to experience some financial distress in the next 2 years | |
| Mayne Pharma Group has accumulated 413.67 M in total debt with debt to equity ratio (D/E) of 0.74, which is about average as compared to similar companies. Mayne Pharma Group has a current ratio of 0.82, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Mayne Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Mayne Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mayne Pharma Group sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mayne to invest in growth at high rates of return. When we think about Mayne Pharma's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 423.92 M. Net Loss for the year was (263.34 M) with profit before overhead, payroll, taxes, and interest of 171.03 M. | |
| Mayne Pharma Group has accumulated about 98.01 M in cash with (7.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06. | |
| Roughly 23.0% of Mayne Pharma outstanding shares are owned by corporate insiders |
Other Information on Investing in Mayne Pink Sheet
Mayne Pharma financial ratios help investors to determine whether Mayne Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mayne with respect to the benefits of owning Mayne Pharma security.